非注射インスリン市場-世界の産業規模、シェア、動向、機会、予測、2018～2028年、製品別、流通チャネル別、地域別、競合

世界の非注射インスリン市場は、2022年に26億9,000万米ドルの評価を達成し、予測期間を通じて大幅な成長の態勢を整えており、9.10％の堅調な年間平均成長率（CAGR）を維持し、2028年には45億1,000万米ドルに達すると予測されています。

このダイナミックな市場セグメントは、注射を必要としない投与用に調整された多様なインスリン製剤を包含しています。これらの革新的な選択肢は、糖尿病に対処している個人に対応し、従来の注射方法に関連する課題や注射に対するアレルギー反応に対処します。非注射型インスリン製剤の選択肢は、経口剤、吸入剤、パッチ剤、新たな送達方法など多岐にわたる。

主な市場促進要因

• 1.血糖コントロールの改善：世界の非注射インスリン市場は、血糖コントロールの進歩から大きな恩恵を受けています。このカテゴリーには、吸入インスリン、経口インスリン、経皮インスリン送達システムなど、従来の針注射の必要性をなくすインスリン送達方法が含まれます。血糖コントロールの一貫性は、糖尿病管理における主要な課題です。注射インスリンは、不快感、痛み、注射針への不安のために、処方されたインスリンレジメンへの患者のアドヒアランスを阻害する可能性があります。非注射インスリン法は、より便利で侵襲の少ない代替法を提供し、患者のコンプライアンスを高める可能性があります。糖尿病管理と血糖コントロールの改善は、合併症と入院のリスクを軽減します。非注射インスリン製剤、特に投与が容易な製剤は、糖尿病管理への早期介入を促すことができます。早期のインスリン治療開始は血糖コントロールを改善し、疾患の進行を遅らせ、糖尿病関連の医療コストを削減しながら長期的な転帰を改善します。非注射型インスリン製剤は、糖尿病患者、特に注射針を嫌がる患者や身体的制限のある患者にとって治療の選択肢を広げ、血糖コントロールを向上させる可能性があります。これらの方法は、これまで注射への恐怖感からインスリン治療の開始をためらっていた新しい患者層を惹きつけ、市場の成長に貢献します。

• 2.糖尿病人口の増加糖尿病人口の拡大は、世界の非注射インスリン市場に大きな影響を与えています。血糖値の上昇を特徴とする糖尿病は、世界的に有病率が上昇しており、非注射インスリンを含む効果的で利便性の高い治療薬に対する需要を牽引しています。糖尿病人口が増え続けるにつれ、インスリン療法を含む多様な糖尿病管理ソリューションに対する需要が高まっています。非注射インスリン法は、従来の注射インスリンを使いたくない、あるいは使えない人々に代替ソリューションを提供します。このような便利で患者に優しい治療に対する需要の高まりが、市場の拡大に寄与しています。非注射型インスリン製剤は、注射針を嫌がる患者や注射が苦手な患者など、より幅広い患者に対応します。糖尿病人口の増加は、多様な年齢層や背景にまたがっているため、吸入インスリンや経口インスリンなどの非注射インスリン製剤は、あらゆる層に受け入れられやすくなっています。糖尿病治療計画の遵守は、効果的な血糖コントロールを達成し合併症を回避するために極めて重要です。しかし、多くの糖尿病患者は、注射針に対する恐怖心や不便さから、注射によるインスリン療法を継続することが困難です。非注射インスリン製剤は、利便性と使いやすさを向上させ、より良いアドヒアランスと予後をもたらす可能性があります。糖尿病人口の急増に伴い、早期介入と予防対策が注目されています。非注射インスリン製剤の選択肢は、より早期にインスリン治療を開始することを促し、血糖コントロールを強化することができます。早期介入は糖尿病に関連する合併症を遅らせたり予防したりし、医療コストを抑制し、患者のQOLを向上させる。糖尿病有病率の増加は、革新的な糖尿病管理製品に大きな市場機会をもたらし、研究開発および商業化への努力を促し、市場の成長を促進しています。
• 3.製薬業界の投資：製薬業界の投資は、世界の非注射インスリン市場の成長軌道を左右する極めて重要な役割を果たしています。これらの投資には、非注射インスリン製剤に関する研究開発、臨床試験、製造、マーケティング、流通などの取り組みが含まれます。製薬会社は、革新的な非注射インスリン製剤の送達方法に焦点を当て、研究開発に多大なリソースを割いています。これらの投資は、インスリン治療の利便性と患者の利便性を高める新しい技術、製剤、投与経路の探求に拍車をかけています。このような投資による進歩は、新規で効果的な治療法の導入による市場の拡大を促進します。製薬業界の投資は、非注射インスリン分野での技術革新を刺激し、改善された有効性、安全性、患者体験を誇る製品の創出を目指します。技術革新には、より正確な投与メカニズム、徐放性製剤、最適化された送達システムなどが含まれます。こうした進歩は医療専門家や患者の注目を集め、市場の採用と成長を後押しします。厳格な臨床試験は、新しい医薬品を市場に投入する上で極めて重要なステップです。このような臨床試験への投資は、非注射インスリン製剤の安全性と有効性を検証し、規制当局の承認に必要なデータを提供します。肯定的な試験結果は、医療界に信頼を与え、これらの製品の幅広い採用を促進し、市場の成長を促進します。業界は、非注射型インスリン製剤について医療専門家や患者に情報を提供するための教育的な取り組みにも投資しています。教育プログラムは、医療従事者が十分な情報を得た上で治療を決定し、患者が適切な選択肢を選択できるよう支援します。認知度の向上は採用率の上昇を促し、市場成長にプラスの影響を与えます。

主な市場課題

• 1.有効性と安全性への懸念：有効性と安全性の懸念は、世界の非注射型インスリン市場の成長に障害をもたらす可能性があります。非注射型インスリン製剤は従来の注射に代わる便利な製剤であるが、医療従事者、規制当局、患者の信頼を得るためには、これらの懸念に対処することが極めて重要です。有効性に関する懸念は、非注射インスリン製剤が注射インスリン製剤に匹敵する一貫した信頼性の高い血糖コントロールを提供するという臨床エビデンスが不十分な場合に生じる。医療専門家と患者は、その有効性の明確なエビデンスがない限り、注射以外の選択肢に移行することをためらうかもしれないです。もし非注射インスリン製剤が一貫性のない、あるいは予測不可能な血糖値をもたらすならば、患者や医療プロバイダーは、注射インスリン製剤よりも信頼性が低いと認識し、糖尿病管理に対する長期的な信頼を損なうかもしれないです。安全性に関する懸念には、副作用、副作用、他の薬剤との相互作用の可能性などが含まれます。これらの製品の安全性を確保することは、規制当局の承認を確保し、患者や医療従事者の信頼を築く上で極めて重要です。非注射型インスリン製剤、特に新しい送達技術の長期的な影響については、まだ十分に理解されていない可能性があります。患者や医療プロバイダーは、長期使用後に生じる可能性のある合併症について懸念を示し、これらの方法を採用する意欲に影響を与える可能性があります。
• 2.コストと手頃な価格：コストと手頃な価格は、世界の非注射インスリン市場の成長を阻害する重要な要因です。非注射型インスリン製剤は、利便性や患者の利便性という点では利点があるが、従来の注射型インスリン製剤に比べてコストが高くなる場合があります。非注射型インスリン製剤は、より複雑な技術、研究開発を伴うことが多く、その結果、製造コストが上昇します。その結果、非注射インスリン製剤の初期購入価格は注射インスリンのそれを上回るかもしれないです。このコスト差は、患者や医療プロバイダーが注射以外の選択肢を選ぶことを躊躇させる可能性があります。保険適用や償還政策は、非注射型インスリン製剤の費用を完全にカバーしない可能性があり、患者は、支払うことが困難となる可能性のある自己負担額を強いられることになります。このような保険適用の欠如は大きな障壁となり、患者がこれらの代替療法を利用することを妨げ、市場の成長を阻害します。糖尿病患者は、投薬、モニタリング機器、医師の診察などに関連する継続的な医療費と頻繁に闘うことになります。非注射型インスリン製剤の費用をこれらの費用に組み込むことは、患者に経済的負担を強いることになり、より経済的な代替品を選択せざるを得なくなります。先進的な非注射型インスリン製剤、特により高性能なインスリン製剤の中には、医療資源が限られている低所得地域では、アクセスしにくい、あるいは手が届かないものもあります。このような格差は健康格差を助長し、世界市場の拡大を妨げる可能性があります。競合情勢には、長年市場で存在感を示してきた注射用インスリン製剤が含まれます。注射剤に代わる新たなインスリン製剤は、市場シェアを確保するために価格競争を強いられる可能性があり、製造コストが高ければ困難となる可能性があります。

主な市場動向

• 1.個別化治療アプローチ：個別化された治療アプローチにより、医療プロバイダーは患者の病歴、ライフスタイル、嗜好に基づいて最適な非注射型インスリン製剤を選択できるようになります。このようなオーダーメイドのアプローチは、治療アドヒアランスと良好な転帰の可能性を高め、非注射法の採用を促進します。患者が治療計画に参加し、自分の嗜好に沿った選択肢を選ぶことができれば、治療に満足する可能性が高くなります。利便性と患者の利便性を提供する非注射型インスリン製剤は、患者満足度の向上に寄与し、市場成長を促進します。患者は、注射針への不安や痛みへの恐怖など、従来の注射に対する懸念を抱いているかもしれないです。個別化された治療アプローチは、非注射インスリン代替品を提示することでこれらの懸念に対処し、患者の快適性と受容性を高める可能性があります。さまざまな年齢層が、さまざまな嗜好や要求を抱いています。例えば、高齢者は手先が不自由なため注射に苦労するかもしれないし、幼児は従来のインスリン注射に苦労するかもしれないです。非注射型インスリン製剤は、このような年齢特有の課題に合わせて調整することができ、市場範囲を拡大することができます。パーソナライズされたアプローチは、日常生活、仕事のスケジュール、食習慣を含む患者のライフスタイルを考慮したものです。患者のライフスタイルに合わせた非注射型インスリン製剤は採用される可能性が高く、市場の成長を促進します。糖尿病管理は、合併症を予防する上で極めて重要です。個別化された治療計画は特定の危険因子を対象にすることができ、血糖コントロール不良に関連する合併症を回避するために患者が最も効果的な治療を受けられるようにします。このアプローチは、患者のニーズに応える非注射型インスリン製剤の採用を促進します。
• 2.規制と償還の進歩：非注射インスリンを含む医薬品の安全性と有効性を確保する上で、規制機関は大きな影響力を行使します。革新的な送達方法に特化して設計された規制経路の進歩は、承認プロセスを迅速化し、非注射インスリンの研究開発に投資する製薬会社の動機付けとなります。合理化された規制経路は製品参入を加速させ、メーカーが非注射インスリンの研究開発に投資する動機付けとなります。強固な規制ガイドラインは、メーカーに製品開発と臨床試験のための明確なロードマップを提供し、革新的な製品を市場に投入する一方で、特定の基準へのコンプライアンスを保証します。リスクベースの監督を採用する規制機関は、非注射インスリン製剤の特徴に合わせた評価プロセスを採用し、厳しい安全基準とこれらの送達システムがもたらすユニークな利点と課題のバランスをとっています。非注射インスリン製剤の適応拡大を認める規制の進歩は、潜在的な患者層を広げます。多様な糖尿病型や特定の患者グループに対する承認を得ることで、市場への働きかけが強化されます。非注射型インスリン製剤に対する保険適用が改善されたことで、医療プロバイダーは非注射型インスリン製剤を処方するようになります。償還政策が強化されることにより、患者の経済的障壁が軽減され、非注射インスリンがより利用しやすくなり、採用に拍車がかかります。製薬会社と支払者（保険プロバイダーや政府の医療プログラム）のコラボレーションは、相互に有利な合意を得ることができます。非注射インスリン製剤の価格設定と償還条件の交渉は、患者にとって手頃な価格を保証し、採用と市場拡大を促進します。規制と償還政策の国際的な調整により、複数地域での同時市場参入が容易になり、障壁が軽減され、非注射インスリン製剤の世界の拡大が加速します。

セグメント別洞察

タイプ別洞察：製品カテゴリーでは、錠剤が予測期間を通じて大幅な市場成長を遂げる見通しです。この成長には、以下のようないくつかの要因が寄与している：

多くの糖尿病患者における注射針に対する嫌悪感や恐怖感：経口インスリン製剤は、より快適で慣れ親しんだ投薬方法を提供し、インスリン治療に対する心理的障壁を軽減します。

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 非注射インスリンの世界市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品別（錠剤、スプレー、その他）
  • 流通チャネル別（病院薬局、オンライン薬局、ドラッグストア）
  • 地域別（北米、欧州、アジア太平洋、南米、中東・アフリカ）
  • 企業別（2022年）
• 市場マップ
  • 製品別
  • 流通チャネル別
  • 地域別

第6章 北米の非注射インスリン市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品別
  • 流通チャネル別
  • 国別
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州の非注射インスリン市場展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • 製品別
  • 流通チャネル別
  • 国別
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋の非注射インスリン市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品別
  • 流通チャネル別
  • 国別
• アジア太平洋：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米の非注射インスリン市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品別
  • 流通チャネル別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの非注射インスリン市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品別
  • 流通チャネル別
  • 国別
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の展開
• 合併・買収
• 製品発表

第13章 非注射インスリンの世界市場のSWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 競合情勢

• Midatech Pharma Plc
• Shreya Life Sciences Pvt. Ltd.
• Boston Therapeutics, Inc.
• Coromed, Inc.
• Diabetology Ltd.
• Emisphere Technologies, Inc.
• Oramed Pharmaceuticals, Inc.
• Diasome Pharmaceuticals, Inc.
• Generex Biotechnology Corp.
• Biodel, Inc.

第16章 戦略的提言

Global Non-Injectable Insulin Market is anticipated to project robust growth in the forecast period. The non-injectable insulin market comprises various insulin formulations designed for administration without injections. These alternatives offer options for individuals with diabetes who face challenges with conventional injection techniques or have allergies to injections. Non-injectable options include oral, inhalable, patches, and other emerging delivery methods.

Key Market Drivers

Improved Glycemic Control

Improved glycemic control can have a significant influence on the growth of the global non-injectable insulin market. Non-injectable insulin refers to insulin delivery methods that do not involve traditional needle injections, such as inhalable insulin, oral insulin, and transdermal insulin delivery systems. One of the main challenges in diabetes management is maintaining consistent glycemic control. Injectable insulin may lead to discomfort, pain, and needle anxiety, which can deter some patients from adhering to their prescribed insulin regimen. Non-injectable insulin methods offer more convenient and less invasive options, potentially increasing patient compliance. When patients can manage their diabetes more effectively, it leads to improved glycemic control, reducing the risk of complications and hospitalizations. Non-injectable insulin methods, especially those that are easier to administer and less intimidating, can encourage earlier intervention in diabetes management. By starting insulin therapy earlier in the disease progression, patients can achieve better glycemic control and slow down the progression of the disease. This can lead to better long-term outcomes and reduced healthcare costs associated with diabetes-related complications. Improved glycemic control with non-injectable insulin methods offers a wider range of treatment options for individuals with diabetes. This is especially important for patients who may have a fear of needles or struggle with injections due to physical limitations. By offering multiple routes of administration, healthcare providers can tailor treatment plans to individual patient needs, potentially leading to better glycemic control. Improved glycemic control achieved through non-injectable insulin methods can attract new patient populations, including those who may have been hesitant to start insulin therapy due to the fear of injections. This expansion of the patient base can contribute to market growth.

Growing Diabetic Population

The growing diabetic population has a substantial influence on the growth of the global non-injectable insulin market. Diabetes is a chronic condition characterized by high blood sugar levels, and its prevalence has been increasing globally. This rise in the number of people with diabetes directly impacts the demand for effective and convenient treatment options, such as non-injectable insulin. As the diabetic population continues to grow, the demand for various diabetes management solutions, including insulin therapies, also increases. Non-injectable insulin methods provide alternative options for those who may be reluctant or unable to use traditional injectable insulin. This increased demand for more convenient and patient-friendly treatment options contributes to the growth of the non-injectable insulin market. Non-injectable insulin methods can cater to a broader range of patients, including those who are hesitant to use needles or have difficulty with injections. The growing diabetic population includes individuals from diverse backgrounds and age groups. Non-injectable insulin products, such as inhalable insulin or oral insulin, provide options that are more acceptable to different segments of the population, thus expanding the potential patient base. Adherence to diabetes treatment plans is essential for achieving good glycemic control and preventing complications. However, many diabetic patients struggle with adhering to injectable insulin regimens due to factors like fear of needles or inconvenience. Non-injectable insulin methods offer improved convenience and ease of use, potentially leading to better treatment adherence and outcomes. With a larger diabetic population, there is a greater emphasis on early intervention and preventive measures. Non-injectable insulin options can encourage individuals to start insulin therapy earlier in their disease progression, leading to better glycemic control. Early intervention can potentially delay or prevent the onset of diabetes-related complications, reducing healthcare costs and improving patients' quality of life. The increasing prevalence of diabetes has led to a significant market opportunity for innovative diabetes management products. Manufacturers and researchers are motivated to develop new and improved non-injectable insulin technologies to meet the diverse needs of the growing diabetic population. This drives investment in research, development, and commercialization of these products, thereby fostering market growth.

Pharmaceutical Industry Investment

Pharmaceutical industry investments play a significant role in influencing the growth of the global non-injectable insulin market. These investments encompass research and development (R&D), clinical trials, manufacturing, marketing, and distribution efforts related to non-injectable insulin products. Pharmaceutical companies allocate substantial resources to R&D for developing innovative non-injectable insulin delivery methods. These investments go into exploring new technologies, formulations, and administration routes that make insulin therapy more convenient and patient-friendly. Advancements resulting from these investments contribute to the expansion of the market by introducing novel and effective treatment options. Pharmaceutical industry investments drive innovation in the non-injectable insulin sector. Companies aim to create products with improved efficacy, safety, and patient experience. Innovations could include more accurate dosing mechanisms, longer-lasting formulations, and optimized delivery systems. Such advancements attract healthcare professionals and patients, boosting market adoption and growth. Rigorous clinical trials are a crucial part of bringing new pharmaceutical products to market. Industry investments in these trials validate the safety and efficacy of non-injectable insulin methods, providing the data needed for regulatory approvals. Positive trial results build confidence in the medical community and encourage wider adoption of these products, driving market growth. Industry investments often extend to educational initiatives aimed at informing healthcare professionals and patients about non-injectable insulin methods. Educational programs help healthcare providers make informed treatment decisions and empower patients to choose suitable options. Improved awareness leads to higher adoption rates, positively impacting market growth.

Key Market Challenges

Efficacy and Safety Concerns

Efficacy and safety concerns can indeed hinder the growth of the global non-injectable insulin market. While non-injectable insulin methods offer convenient and patient-friendly alternatives to traditional injections, addressing these concerns is essential to gain the trust of healthcare professionals, regulators, and patients. Efficacy concerns arise when there is insufficient clinical evidence to demonstrate that non-injectable insulin methods provide consistent and reliable blood sugar control comparable to injectable insulin. Healthcare professionals and patients may be hesitant to switch to non-injectable options without clear evidence of their effectiveness. If non-injectable insulin products result in inconsistent or unpredictable blood sugar levels, patients and healthcare providers may view them as less reliable than injectable insulin. This can lead to skepticism about their long-term effectiveness in managing diabetes, inhibiting market growth. Safety concerns related to non-injectable insulin methods encompass issues such as adverse reactions, side effects, and potential interactions with other medications. Ensuring the safety of these products is critical to gaining regulatory approvals and building trust among patients and healthcare professionals. The long-term effects of non-injectable insulin methods may not be fully understood, especially for novel delivery technologies. Healthcare providers and patients may worry about potential complications that could arise after extended use, impacting the willingness to adopt these methods.

Cost and Affordability

Cost and affordability are significant factors that can hinder the growth of the global non-injectable insulin market. While non-injectable insulin methods offer advantages in terms of convenience and patient-friendliness, they can sometimes come with higher costs compared to traditional injectable insulin. Non-injectable insulin methods often involve more complex technology, research, and development, which can lead to higher production costs. As a result, the initial purchase price of non-injectable insulin products can be higher than that of injectable insulin. This cost difference may discourage patients and healthcare providers from choosing non-injectable options. Insurance coverage and reimbursement policies may not fully cover the costs of non-injectable insulin methods. Patients may face out-of-pocket expenses that they find challenging to afford. This lack of coverage can be a significant barrier, preventing patients from accessing these options and inhibiting market growth. Individuals with diabetes often have ongoing healthcare expenses related to medications, monitoring equipment, doctor visits, and more. Adding the cost of non-injectable insulin methods to these expenses can create a significant financial burden for patients, leading them to opt for more affordable alternatives. Non-injectable insulin products, especially the more advanced ones, may not be accessible or affordable in low-income countries with limited healthcare resources. This can result in health disparities and hinder the global expansion of the market. The competitive landscape includes established injectable insulin products that have been on the market for a long time. New non-injectable options may need to compete on pricing to gain market share, which could be challenging if production costs are higher.

Key Market Trends

Personalized Treatment Approaches

Personalized approaches enable healthcare providers to choose the most suitable non-injectable insulin method based on a patient's medical history, lifestyle, and preferences. This tailored approach increases the likelihood of treatment adherence and successful outcomes, driving the adoption of non-injectable methods. When patients have a say in their treatment plans and can choose options that align with their preferences, they are more likely to be satisfied with their care. Non-injectable insulin methods that offer convenience and patient-friendliness contribute to higher patient satisfaction and the growth of the market. Patients may have concerns about traditional injections, such as needle anxiety or fear of pain. Personalized treatment approaches can address these concerns by offering non-injectable insulin alternatives, which can lead to greater patient comfort and acceptance. Different age groups have varying preferences and needs. For example, elderly individuals may struggle with injections due to reduced dexterity, and young children may have difficulties with traditional insulin injections. Non-injectable insulin methods can be tailored to these age-specific challenges, expanding the market's reach. Personalized approaches consider patients' lifestyles, such as their daily routines, work schedules, and dietary habits. Non-injectable insulin options that align with patients' lifestyles are more likely to be adopted, leading to market growth. Diabetes management is crucial to prevent complications. Personalized treatment plans can target specific risk factors, ensuring that patients receive the most effective treatment to prevent complications associated with poor glycemic control. This approach encourages the adoption of non-injectable insulin methods that suit the patient's needs.

Regulatory and Reimbursement Advancements

Regulatory agencies play a crucial role in ensuring the safety and efficacy of medical products, including non-injectable insulin. Advancements in regulatory pathways that specifically address innovative delivery methods can expedite the approval process. A faster regulatory pathway encourages manufacturers to invest in non-injectable insulin research and development, leading to quicker market entry. Clear and supportive regulatory guidelines for non-injectable insulin methods provide manufacturers with a roadmap for product development and clinical trials. These guidelines ensure that developers meet specific standards while bringing innovative products to market, fostering innovation and growth. Regulatory agencies adopting risk-based oversight can tailor their evaluation processes to the unique characteristics of non-injectable insulin methods. This approach ensures that rigorous safety standards are met while accommodating the specific benefits and challenges of these delivery systems. Regulatory advancements that allow for expanded indications for non-injectable insulin methods increase their potential patient populations. For example, gaining approval for different types of diabetes or specific patient groups can significantly broaden the market reach. Reimbursement advancements that offer better coverage for non-injectable insulin methods encourage healthcare providers to prescribe these options. Improved reimbursement policies reduce financial barriers for patients, making non-injectable insulin more accessible and encouraging adoption. Collaboration between pharmaceutical companies and payers (insurance providers, government healthcare programs) can lead to mutually beneficial agreements. Negotiating pricing and reimbursement terms for non-injectable insulin products ensures that they are affordable for patients, driving adoption and market expansion. International alignment of regulatory and reimbursement policies can facilitate simultaneous market access in multiple regions. This harmonization reduces barriers and accelerates the global expansion of non-injectable insulin products.

Segmental Insights

Type Insights

Based on the Product, the pills segment is anticipated to witness substantial market growth throughout the forecast period. This growth can be attributed to multiple factors, such as Many individuals with diabetes have an aversion to needles or injections. Oral insulin pills offer a more comfortable and familiar form of medication delivery, reducing the psychological barrier to insulin therapy. This increased patient acceptance can lead to higher adoption rates and market growth. The convenience of taking an insulin pill compared to an injection can enhance treatment adherence. Patients may be more likely to follow their prescribed treatment plan consistently when it involves a simple and easy-to-take pill. Improved adherence contributes to better glycemic control and overall patient outcomes. Oral insulin pills can encourage early intervention in diabetes management. Individuals who are hesitant to start injectable insulin therapy might be more open to trying oral pills. Early intervention can lead to better blood sugar control and prevention of complications, driving market growth. Oral insulin pills can attract a wider patient base, including those who were previously resistant to insulin therapy due to injection-related fears or concerns. This expansion of the patient population can contribute to market growth. Pills empower patients to take charge of their diabetes management independently. Patients can easily carry and administer their medication without the need for medical personnel or specialized equipment, leading to greater patient empowerment and engagement.

End Use Insights

Based on the end-use segment, the Drug Stores segment has been the dominant force in the market. Drug stores are often conveniently located in urban and suburban areas, making them easily accessible to patients. This accessibility ensures that non-injectable insulin products are readily available to a broad patient population. Pharmacists at drug stores are trained healthcare professionals who can provide patients with information about non-injectable insulin options. They can explain how these products work, their benefits, and administration techniques, enhancing patient awareness and understanding. Drug stores are essential points for patients to pick up their prescribed medications, including non-injectable insulin products. Pharmacists can guide patients on proper usage, storage, and potential side effects, promoting adherence and positive treatment outcomes. Some non-injectable insulin products may be available over-the-counter, allowing patients to purchase them without a prescription. Drug stores can stock these OTC options, giving patients greater autonomy in managing their diabetes. Some drug stores offer health screenings, including blood glucose testing. Pharmacists can use these opportunities to educate patients about non-injectable insulin methods and encourage them to consider these alternatives. Drug stores can actively promote non-injectable insulin options through in-store displays, brochures, and informational sessions. This promotion raises patient awareness and encourages them to explore these alternatives.

Regional Insights

North America, specifically the Non-Injectable Insulin Market, dominated the market in 2022, primarily due to North America, particularly the United States and Canada, boasts advanced healthcare systems, research institutions, and pharmaceutical industries. This infrastructure supports the development, clinical testing, and commercialization of innovative medical products like non-injectable insulin. The region is a hub for technological innovation, which includes advancements in drug delivery systems. Non-injectable insulin methods require sophisticated technology, and North America's innovation ecosystem facilitates the development of these technologies. The pharmaceutical industry in North America is robust, with many companies investing in research and development. These companies have the resources to develop and market non-injectable insulin products, driving growth. North America is often a preferred location for conducting clinical trials due to its diverse population, well-established regulatory framework, and skilled medical professionals. Clinical trials are crucial for demonstrating the safety and efficacy of new medical products. Public awareness campaigns and healthcare initiatives help educate patients about various treatment options. As patients become more aware of non-injectable insulin methods, they are likely to express interest, driving demand. Patient preferences for non-injectable insulin options align with the convenience and ease of use offered by these methods. Meeting patient preferences drives adoption and market growth.

Key Market Players

• Midatech Pharma Plc

• Shreya Life Sciences Pvt. Ltd.

• Boston Therapeutics, Inc.

• Coromed, Inc.

• Diabetology Ltd.

• Emisphere Technologies, Inc.

• Oramed Pharmaceuticals, Inc.

• Diasome Pharmaceuticals, Inc.

• Generex Biotechnology Corp.

• Biodel, Inc.

Report Scope:

In this report, the Global Non-Injectable Insulin Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Non-Injectable Insulin Market, By Product:

• Pills
• Sprays
• Others

Non-Injectable Insulin Market, By Distribution Channel:

• Hospital Pharmacies
• Online Pharmacies
• Drug Stores

Non-Injectable Insulin Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait
• Turkey
• Egypt

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Non-Injectable Insulin Market.

Available Customizations:

• Global Non-Injectable Insulin market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Non-Injectable Insulin Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Pills, Sprays, and Others)
  • 5.2.2. By Distribution Channel (Hospital Pharmacies, and Online Pharmacies, Drug Stores)
  • 5.2.3. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
  • 5.2.4. By Company (2022)
• 5.3. Market Map
  • 5.3.1 By Product
  • 5.3.2 By Distribution Channel
  • 35.3.4 By Region

6. North America Non-Injectable Insulin Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product (Pills, Sprays, and Others)
  • 6.2.2. By Distribution Channel (Hospital Pharmacies, and Online Pharmacies, Drug Stores)
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Non-Injectable Insulin Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Distribution Channel
  • 6.3.2. Canada Non-Injectable Insulin Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Distribution Channel
  • 6.3.3. Mexico Non-Injectable Insulin Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Distribution Channel

7. Europe Non-Injectable Insulin Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product (Pills, Sprays, and Others)
  • 7.2.2. By Distribution Channel (Hospital Pharmacies, and Online Pharmacies, Drug Stores)
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Non-Injectable Insulin Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Distribution Channel
  • 7.3.2. Germany Non-Injectable Insulin Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Distribution Channel
  • 7.3.3. United Kingdom Non-Injectable Insulin Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Distribution Channel
  • 7.3.4. Italy Non-Injectable Insulin Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Distribution Channel
  • 7.3.5. Spain Non-Injectable Insulin Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Distribution Channel

8. Asia-Pacific Non-Injectable Insulin Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product (Pills, Sprays, and Others)
  • 8.2.2. By Distribution Channel (Hospital Pharmacies, and Online Pharmacies, Drug Stores)
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Non-Injectable Insulin Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Distribution Channel
  • 8.3.2. India Non-Injectable Insulin Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Distribution Channel
  • 8.3.3. Japan Non-Injectable Insulin Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Distribution Channel
  • 8.3.4. South Korea Non-Injectable Insulin Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Distribution Channel
  • 8.3.5. Australia Non-Injectable Insulin Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Distribution Channel

9. South America Non-Injectable Insulin Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product (Pills, Sprays, and Others)
  • 9.2.2. By Distribution Channel (Hospital Pharmacies, and Online Pharmacies, Drug Stores)
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Non-Injectable Insulin Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Distribution Channel
  • 9.3.2. Argentina Non-Injectable Insulin Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Distribution Channel
  • 9.3.3. Colombia Non-Injectable Insulin Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Distribution Channel

10. Middle East and Africa Non-Injectable Insulin Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product (Pills, Sprays, and Others)
  • 10.2.2. By Distribution Channel (Hospital Pharmacies, and Online Pharmacies, Drug Stores)
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Non-Injectable Insulin Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Distribution Channel
  • 10.3.2. Saudi Arabia Non-Injectable Insulin Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Distribution Channel
  • 10.3.3. UAE Non-Injectable Insulin Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Global Non-Injectable Insulin Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Business Overview
• 15.2. Product Offerings
• 15.3. Recent Developments
• 15.4. Financials (As Reported)
• 15.5. Key Personnel
• 15.6. SWOT Analysis
  • 15.6.1 Midatech Pharma Plc
  • 15.6.2 Shreya Life Sciences Pvt. Ltd.
  • 15.6.3 Boston Therapeutics, Inc.
  • 15.6.4 Coromed, Inc.
  • 15.6.5 Diabetology Ltd.
  • 15.6.6 Emisphere Technologies, Inc.
  • 15.6.7 Oramed Pharmaceuticals, Inc.
  • 15.6.8 Diasome Pharmaceuticals, Inc.
  • 15.6.9 Generex Biotechnology Corp.
  • 15.6.10 Biodel, Inc.

16. Strategic Recommendations